Earnings Call · Q2 FY2021·2021-08-11

Q2 21EPS -4.08%·Rev n/aQ1 21EPS -7.69%·Rev n/aQ4 20EPS +15.00%·Rev n/aQ3 20EPS -47.06%·Rev n/a⚠ consensus missing

Xenon Pharmaceuticals Inc. XENE

Jodi Regts — Investor Relations or Communications Executive

Ian Mortimer — President and Chief Executive Officer

Simon Pimstone — Executive Chair of the Board

Chris Von Seggern — Market Research or Commercial Strategy Executive

Sherry Aulin — Finance Executive

−4.4%1d on move date−4.7% vs SPY3d−5.0%5d−9.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XENE calls or request research access.

More XENE calls Browse calls Request research access